Transcatheter Technologies reports first-in-human implantation of transapical TRINITY aortic valve

Oct 25 2013

Transcatheter Technologies GmbH, a emerging medical device company that is developing a next-generation transcatheter aortic heart valve prosthesis, announced today the successful first-in-human implantation of its transapical TRINITY aortic valve designed to be the world's best repositionable heart valve.

"A major limitation of existing transcatheter aortic heart valves is that they cannot be repositioned once implanted. Trinity, however, is designed to solve this difficult problem," said Wolfgang Goetz, MD, PhD, CEO, a cardiac surgeon by training. "With Trinity, once our valve is initially placed, a cardiologist can fully evaluate the valve's function to determine whether it needs to be repositioned, retrieved, or kept in the same position. Equally important, Trinity provides for a controlled positioning by allowing a cardiologist to slowly open the valve stent, thus improving the likelihood of a first-attempt correct placement."

"The TRINITY aortic valve can be positioned precisely. Yet, it also allows for safe repositioning of the valve prosthesis—or even full retrieval—if necessary. Its unique sealing cuff provides excellent results without paravalvular leakage. Moreover, the risk for atrio-ventricular block is dramatically reduced due to the supraannular positioning of TRINITY," added Prof. Christian Hengstenberg, cardiologist at the German Heart Center in Munich.

The results of the first-in-human clinical trial using Trinity will be presented at the annual TCT Meeting in San Francisco on Monday, October 28, 2013.

Source: Transcatheter Technologies GmbH